Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide
- Author(s)
- Youngil Koh; Soo-Mee Bang; Jae Hoon Lee; Hwi-Joong Yoon; Young-Rok Do; Hun-Mo Ryoo; Nari Lee; Seok Jin Kim; Kihyun Kim; Sung-Soo Yoon; Jong-Ho Won; Yeung-Chul Mun; Moon-Hee Lee; Ki-Hyun Rhee; Hyo-Jung Kim; HyeonSeok Eom; Min Kyoung Kim; Hyun Chun Shin
- Keimyung Author(s)
- Do, Young Rok
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Annals of Hematology
- Issued Date
- 2010
- Volume
- 89
- Issue
- 2
- Abstract
- The frequency of thromboembolic events (TE) in
Caucasian patients with multiple myeloma (MM) receiving
thalidomide as the initial treatment has been reported to be
10~58% without prophylactic anticoagulation. Korean MM
patients treated with thalidomide were studied to determine
the frequency of TE and associated risk factors. A
retrospective medical record review of the Korean MM
registry from 25 centers in Korea between 2003 and 2007was performed. We assessed the incidence of arterial and
venous TE and the associated clinical parameters. Three
hundred and sixty MM patients (median age 61 years,
range 32–88 years) received thalidomide treatment. Fourteen
patients (3.9%) developed TE: 12 had venous and two
had arterial locations. The sites for the venous TE included
lungs (seven), lower extremities (four), upper extremities
(one), and neck (one). Arterial TE developed in cerebral
and peripheral arteries each. No single clinical parameter
such as prerequisite for the metabolic syndrome, disease
status, and treatment regimen were predictive for the
development of TE. The frequency of TE in patients who
received thalidomide as initial therapy (7/155) was not
different from those who received thalidomide for progressive
or relapsed disease (7/205, p=0.592). The frequency of
TE during thalidomide treatment in Korean patients with
MM was low. No significant clinical factor was found to be
a risk factor. The subgroup requiring thromboprophylaxis
among the Korean patients with MM, receiving thalidomide,
needs to be clarified.
Keywords Multiple myeloma . Thalidomide .
Thromboembolism
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.